Stockscreener 앱 받기
0.00
100.00%
-0.0111
Virpax Pharmaceuticals Inc 주식(VRPX)의 최신 뉴스
Top Players and Market Competition in the Non-Opioid Pain Patch Industry - openPR.com
VRPX Stock Plummets 95.5% in Pre-Market Trading on NASDAQ - Meyka
Virpax Pharmaceuticals, Inc. (VRPX) - Minichart
Virpax Pharmaceuticals (VRPX) Expected to Announce Earnings on Tuesday - Defense World
Comparing Virios Therapeutics (NASDAQ:VIRI) & Virpax Pharmaceuticals (NASDAQ:VRPX) - Defense World
VRPX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Petros Pharmaceuticals (NASDAQ:PTPI) versus Virpax Pharmaceuticals (NASDAQ:VRPX) Head-To-Head Contrast - Defense World
Revenue per share of Virpax Pharmaceuticals, Inc. – OTC:VRPX - TradingView
Virpax reports positive study results for pain management drug - MSN
Virpax Pharmaceuticals to conduct reverse stock split - Intellectia AI
Virpax Pharmaceuticals director resigns due to compliance - MSN
Virpax Pharmaceuticals Highlights Leadership Contributions at Clinical Trial Conference - MSN
EBITDA per share of Virpax Pharmaceuticals, Inc. – OTC:VRPX - TradingView — Track All Markets
Virpax Pharmaceuticals Inc. (VRPX) Stock Price | Live Quotes & Charts | EXPM - StocksToTrade
Tangible book value per share of Virpax Pharmaceuticals, Inc. – OTC:VRPX - TradingView — Track All Markets
CapEx per share of Virpax Pharmaceuticals, Inc. – OTC:VRPX - TradingView — Track All Markets
RTW Biotech invests USD5.9 million in Yarrow Bioscience funding round - marketscreener.com
Virpax Pharmaceuticals stock hits 52-week low at $0.29 - MSN
Stocks advance as Nvidia earnings light up global markets - marketscreener.com
Wall Street opens higher as Nvidia test looms - marketscreener.com
Virpax Pharmaceuticals Advances Pain Management with Promising Probudur Study Results - MSN
Jones Expects Nasdaq to Climb Higher, Lower Rates - marketscreener.com
TNF Pharmaceuticals Regains Compliance With Nasdaq Listing Requirement - marketscreener.com
Vinay Shah Net WorthInsider Trades and Bio as of Apr 21, 2026 - Benzinga
Hookipa Pharma to Voluntarily Delist From Nasdaq - marketscreener.com
Nasdaq Announces Delisting of Multiple Companies Including NKGen Biotech, Aquaron Acquisition Corp, and Others - Quiver Quantitative
Virpax and Nanomerics Enter Technology License Agreement for Developing A Product for PTSD Treatment - StatNano
BTAX Stock Price, News & Analysis - Stock Titan
EVLO Stock Price, News & Analysis - Stock Titan
VRPX Stock Price and Chart — OTC:VRPX - TradingView
Virpax Pharmaceuticals stock plummets on Nasdaq delisting news - Investing.com
Virpax Pharmaceuticals enacts 1-for-25 reverse stock split - Investing.com
Virpax Reports on Progress of Envelta™ - Business Wire
Business InsuranceMagazineVirpax Pharmaceuticals Announces Reverse Stock Split - FinancialContent
Virpax receives positive Probudur™ results for dose range study - TradingView
Virpax Looking to Use MET to Develop Intranasal COVID Vaccine - FinancialContent
Can Virpax's Nasal Pain Treatment Solve the Opioid Addiction Problem? - Stock Titan
Virpax Pharmaceuticals Applauds Successful Trial of Molecular Envelope Technology - MyChesCo
VRPX Soars On MET Results, COLL Projects 16%-19% Revenue Growth In 2025, RPID Gains Momentum - RTTNews
Penny Stock Virpax Pharmaceuticals Surges On US Army-Performed Preclinical Study For Pain Candidate - Yahoo Finance
Military Breakthrough: New Pain Control Drug Shows 96-Hour Combat Effectiveness in Army Tests - Stock Titan
Virpax Pharmaceuticals appoints new independent director - MSN
Virpax Pharmaceuticals director resigns due to compliance By Investing.com - Investing.com Nigeria
Virpax's Matthew Barnes to Present at Outsourcing in Clinical Trials Conference - FinancialContent
FinancialContentVirpax Pharmaceuticals, Inc. Announces Closing of $6.0 Million Public Offering of Common Stock and Pre-Funded Warrants - FinancialContent
Virpax Pharmaceuticals names new board director - Investing.com
Virpax Pharmaceuticals lowers quorum requirement By Investing.com - Investing.com Nigeria
User - The Chronicle-Journal
Dow Theory LettersSpartan Capital Securities, LLC Serves as Sole Placement Agent in Virpax Pharmaceuticals, Inc.'s $5.0 Million Public Offering - FinancialContent
Star Tribune - FinancialContent
Maxim Downgrades Virpax Pharmaceuticals to Hold From Buy, Price Target is $173 - marketscreener.com
Virpax Pharmaceuticals Faces Nasdaq Delisting Risk - TipRanks
Virpax Pharmaceuticals faces Nasdaq delisting over equity shortfall By Investing.com - Investing.com UK
Which stocks are moving before the opening bell on Tuesday? - ChartMill
Virpax Pharmaceuticals Reports 2024 Second Quarter Results and Recent Developments - The Chronicle-Journal
Virpax Pharmaceuticals to Present at Sidoti Virtual Investor Conference August 14-15 - The Chronicle-Journal
Virpax Regains Compliance with Nasdaq Minimum Bid Price - The Chronicle-Journal
3 Penny Stocks to Watch Now, 7/23/24 - Nasdaq
Maxim Group Upgrades Virpax Pharmaceuticals (VRPX) - Nasdaq
Maxim Group Upgrades Virpax Pharmaceuticals(VRPX.US) to Buy Rating, Announces Target Price $3 - Moomoo
These stocks have an unusual volume in today's session - ChartMill
What's going on in today's after hours session - ChartMill
Virpax Pharmaceuticals Secures $2.5 Million Loan Financing - citybiz
Virpax® Pharmaceuticals to Present at 2024 BIO International Convention - The Chronicle-Journal
Acute Pain Pipeline Drugs Analysis Report, 2024: FDA Approvals, - openPR.com
Virpax Pharmaceuticals Reports 2024 First Quarter Results and Recent Developments - FinancialContent
Virpax Pharmaceuticals Set for Transformative Year with High Hopes for Non-Addictive Pain Management Solutions - MyChesCo
Virpax Pharmaceuticals Reports 2023 Year-End Results - FinancialContent
2.93%
자본화:
|
볼륨(24시간):